Corrigendum: Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

Front Immunol. 2023 Dec 5:14:1345513. doi: 10.3389/fimmu.2023.1345513. eCollection 2023.

Takashi Shimizu^{1

2}, Eisuke Inoue³, Ryotaro Ohkuma^{1

4}, Shinichi Kobayashi², Takuya Tsunoda⁴, Satoshi Wada^{1

2

4

5

6}

¹ Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
² Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
³ Showa University Research Administration Center, Showa University, Tokyo, Japan.
⁴ Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
⁵ Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
⁶ Pharmacological Research Center, Showa University, Tokyo, Japan.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1308381.].

Keywords: PD-1 inhibitors; advanced non-small cell lung cancer; biomarker; individual patient data meta-analysis; soluble PD-L1.